#16C DB 6/5/03

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on August 30, 2002.

TOWNSEND and TOWNSEND and CREW LLP

By: Rosemarie L. Celli
Rosemarie L. Celli

PATENT
Attorney Docket No.: 15270J-004743US
Client Ref. No.: 209-US-CIP5C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 09/724,319

Filed: November 27, 2000

For: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Art Unit: 1647

SECOND PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE SPECIFICATION:

Please replace the paragraph beginning at line 25 of page 14 with the following replacement paragraph.

C1

Polyclonal sera typically contain mixed populations of antibodies binding to several epitopes along the length of Aβ. Monoclonal antibodies bind to a specific epitope within Aβ that can be a conformational or nonconformational epitope. Some monoclonal antibodies bind to an epitope within residues 1-28 of Aβ (with the first N terminal residue of natural Aβ designated 1). Some monoclonal antibodies bind to an epitope with residues 1-10 of Aβ. Some monoclonal antibodies bind to an epitope with residues 1-16 of Aβ. Some monoclonal